You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High-risk Prostate Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial in Detroit (Educational video)

Not yet recruiting
  • Prostate Cancer
  • Educational video
  • Detroit, Michigan
    Henry Ford Cancer Pavilion
Jul 14, 2023

Prostate Cancer, Newly-Diagnosed Prostate Cancer Trial ([18F]PSMA-1007)

Not yet recruiting
  • Prostate Cancer
  • Newly-Diagnosed Prostate Cancer
  • (no location specified)
Nov 3, 2023

Prostate Cancer, Prostatic Tumors Trial (64Cu-SAR-bisPSMA)

Not yet recruiting
  • Prostate Cancer
  • Prostatic Neoplasms
  • (no location specified)
Sep 21, 2023

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel Trial in Nanjing (Docetaxel injection, Triptorelin Pamoate for

Active, not recruiting
  • Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
  • Docetaxel injection
  • +2 more
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Dec 24, 2022

Prostate Cancer, High Risk Trial in Houston (68Ga-PSMA)

Active, not recruiting
Has Results
  • Prostate Cancer
  • High Risk
  • Houston, Texas
    Houston Methodist
Dec 8, 2022

Diagnostic Strategy of High-risk Prostate Cancer

Not yet recruiting
  • High-risk Prostate Cancer
  • urine collection
  • canine detection
  • Paris, France
    Hopital Bichat - Claude-Bernard
Sep 26, 2022

Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8 Trial (External Beam Radiation Therapy, Stereotactic Body

Not yet recruiting
  • Stage III Prostate Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8
  • External Beam Radiation Therapy
  • Stereotactic Body Radiation Therapy
  • (no location specified)
Jul 20, 2023

Androgen Deprivation Therapy, Locally Advanced Prostate Cancer Trial in Oklahoma City (Relugolix and Enzalutamide)

Not yet recruiting
  • Androgen Deprivation Therapy
  • Locally Advanced Prostate Cancer
  • Relugolix and Enzalutamide
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center at OU Health, University of Oklahoma He
Nov 8, 2023

Prostate Cancer Trial in Bala-Cynwyd (rhPSMA-7.3 (18F))

Not yet recruiting
  • Prostate Cancer
  • rhPSMA-7.3 (18F)
  • Bala-Cynwyd, Pennsylvania
    MidLantic Urology
Mar 22, 2023

Prostate Cancer Trial in Rome (Decapeptyl)

Recruiting
  • Prostate Cancer
  • Rome, Lazio, Italy
  • +2 more
Sep 23, 2022

Radio-guided Surgery With DROP-IN Beta Probe for 68Ga-PSMA, in

Recruiting
  • Prostate Cancer
  • +2 more
    • Milan, Italy
      IEO European Institute of Oncology
    Oct 24, 2022

    High-Risk Prostate Cancer Trial in Portland (Capivasertib, abiraterone acetate)

    Not yet recruiting
    • High-Risk Prostate Cancer
    • Portland, Oregon
      VA Portland Health Care System, Portland, OR
    Jan 17, 2023

    Prostate Cancer Trial (Hypofractionated IMRT Radiation treatment)

    Active, not recruiting
    • Prostate Cancer
    • Hypofractionated IMRT Radiation treatment
    • (no location specified)
    Sep 27, 2022

    Prostate Cancer Trial in Cairo (Prostate Only Radiation, Prostate and Pelvic Lymph Node Radiation)

    Recruiting
    • Prostate Cancer
    • Prostate Only Radiation
    • Prostate and Pelvic Lymph Node Radiation
    • Cairo, Egypt
      National Cancer Institute - Cairo University
    Aug 9, 2022

    Prostate Cancer, Stereotactic Body Radiotherapy, High-risk Trial in Chengdu (stereotactic body radiotherapy)

    Recruiting
    • Prostate Cancer
    • +4 more
    • stereotactic body radiotherapy
    • Chengdu, Sichuan, China
      China, SiChuan
    Jun 18, 2022

    Prostate Cancer Trial in Toronto (Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy))

    Recruiting
    • Prostate Cancer
    • Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Center
    Jul 18, 2022

    Prostate Cancer Trial in New York (Dose escalation)

    Recruiting
    • Prostate Cancer
    • Dose escalation
    • New York, New York
      Weill Cornell Medicine
    Jul 29, 2022

    Prostate Cancer Trial in Rotterdam (Adaptive radiotherapy according to UPRATE protocol)

    Recruiting
    • Prostate Cancer
    • Adaptive radiotherapy according to UPRATE protocol
    • Rotterdam, Zuid-Holland, Netherlands
      Erasmus Medical Centre
    Jul 26, 2022

    Prostate Adenocarcinoma Trial in Dallas (68-Ga PSMA11)

    Not yet recruiting
    • Prostate Adenocarcinoma
    • 68-Ga PSMA11
    • Dallas, Texas
      UT Southwestern Medical Center
    Sep 12, 2023

    Prostate Cancer Trial in Edmonton (18F-PSMA-1007)

    Active, not recruiting
    • Prostate Cancer
    • 18F-PSMA-1007
    • Edmonton, Alberta, Canada
      University of Alberta
    Aug 10, 2022

    Prostate Cancer Trial in Baltimore (Enoblituzumab)

    Active, not recruiting
    Has Results
    • Prostate Cancer
    • Baltimore, Maryland
      Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Aug 16, 2022

    Prostate Cancer, Prostate Adenocarcinoma Trial in Netherlands

    Recruiting
    • Prostate Cancer
    • Prostate Adenocarcinoma
      • Alkmaar, Netherlands
      • +27 more
      Jun 27, 2023

      Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (Olaparib, LHRH agonist)

      Not yet recruiting
      • Prostate Cancer
      • +4 more
      • (no location specified)
      Aug 10, 2022

      Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8 Trial in Atlanta

      Recruiting
      • Stage III Prostate Cancer AJCC v8
      • +3 more
      • High-Dose Rate Brachytherapy
      • +3 more
      • Atlanta, Georgia
        Emory University Hospital/Winship Cancer Institute
      Jul 8, 2022

      Prostate Cancer Trial in Cleveland (Leuprolide acetate, Apalutamide, Radical prostatectomy)

      Completed
      Has Results
      • Prostate Cancer
      • Leuprolide acetate
      • +2 more
      • Cleveland, Ohio
        Cleveland Clinic, Case Comprehensive Cancer Center
      May 25, 2022